Skip to main content

Racial Discrimination Linked to Increased CRP in Black Women With Lupus

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 14, 2023 -- For Black women with systemic lupus erythematosus (SLE), incident racial discrimination is associated with elevated C-reactive protein (CRP), according to a study published in the August issue of Brain, Behavior, and Immunity.

Connor D. Martz, Ph.D., from the University of Texas at Austin, and colleagues examined incident experiences of racial discrimination and changes in inflammatory biomarker CRP during a two-year period among Black women with SLE. A total of 380 participants were enrolled from April 2015 to May 2017. The Experiences of Discrimination measure was used to assess incident racial discrimination biannually via self-report.

The researchers found that across the two-year study period, incident experiences of racial discrimination were associated with elevated log-transformed CRP (b = 0.039). CRP increased 3.98 percent for each domain of incident racial discrimination experienced.

"The results of this study contribute to a growing body of evidence indicating that racial discrimination is a toxic health threat, and that the embodiment of racial discrimination is one pathway through which racism contributes to inequitable health outcomes for Black Americans," the authors write. "Policies and laws aimed at eliminating contemporary and persistent forms of racial discrimination are likely to advance health equity for Black women with SLE, as well as Black Americans more broadly."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

FDA Approves Belimumab Autoinjector for Pediatric Systemic Lupus Erythematosus

WEDNESDAY, May 22, 2024 -- The U.S. Food and Drug Administration has approved a 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and...

Neuropsychiatric Symptoms Can Present at Any Stage of Lupus

TUESDAY, May 21, 2024 -- For patients with systemic lupus erythematosus (SLE), neuropsychiatric (NP) symptoms can first present at any stage in the disease course, according to a...

Rheumatic Diseases Have an Impact on Reproductive Health

WEDNESDAY, April 3, 2024 -- Rheumatic diseases have a broad impact on reproductive success and pregnancy outcomes, according to a study published online March 20...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.